Park HyeYoun, Oh Sohee, Noh Yumi, Kim Ju Young, Kim Jeong-Hyun
1 Department of Psychiatry, Seoul National University Bundang Hospital, Gyeonggi, Republic of Korea.
2 Department of Biostatistics, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Integr Cancer Ther. 2018 Sep;17(3):825-831. doi: 10.1177/1534735418756192. Epub 2018 Feb 8.
We aimed to investigate the effects of brief supportive expressive group therapy with mindfulness for cancer patients and to assess the utility of heart rate variability (HRV) as a biomarker of distress and treatment effect.
A total of 28 female patients with nonmetastatic cancer at a university hospital in South Korea received a 4-week modified group therapy for distress reduction. The BESTMIND (Brief Expression and Support Therapy with Mindfulness) program consisted of supportive-expressive group therapy and mindfulness-based stress reduction. The subjective outcomes of distress, anger, sleep quality, and sense of well-being and the physiological outcome of HRV were assessed before and after the program.
After the program, patients showed significantly reduced distress, perceived stress, anger, and sleep disturbance and increased quality of life. No significant change was observed in the degree of mindfulness. A significantly increased SD in the normal beat-to-beat intervals and normalized high-frequency (HF 0.15-0.4 Hz) power from spectral analysis were observed after treatment. According to the correlation analyses, HF power correlated with depression scores, and normalized HF power was associated with depression, anxiety, perceived stress, and anger at baseline. The pretreatment and posttreatment comparison indicated that an increase in HF power was associated with a decrease in anger.
These results suggest the effectiveness of this modified group-based program for distress reduction and also provide preliminary evidence for the use of HRV as a biomarker of distress and recovery. HF power from HRV variables may serve as a quantitative biomarker of the treatment response of distress management, including anger.
我们旨在研究针对癌症患者的简短支持性表达性团体疗法与正念疗法的效果,并评估心率变异性(HRV)作为痛苦和治疗效果生物标志物的效用。
韩国一所大学医院的28名非转移性癌症女性患者接受了为期4周的减轻痛苦的改良团体疗法。BESTMIND(基于正念的简短表达与支持疗法)项目包括支持性表达团体疗法和基于正念的减压疗法。在项目前后评估了痛苦、愤怒、睡眠质量和幸福感等主观结果以及HRV的生理结果。
项目结束后,患者的痛苦、感知压力、愤怒和睡眠障碍显著减轻,生活质量提高。正念程度未观察到显著变化。治疗后观察到逐搏间期标准差显著增加,频谱分析显示高频(HF 0.15 - 0.4 Hz)功率正常化。根据相关性分析,HF功率与抑郁评分相关,正常化HF功率在基线时与抑郁、焦虑、感知压力和愤怒相关。治疗前与治疗后的比较表明,HF功率增加与愤怒减少相关。
这些结果表明这种改良的团体项目在减轻痛苦方面是有效的,也为将HRV用作痛苦和恢复的生物标志物提供了初步证据。HRV变量中的HF功率可能作为包括愤怒在内的痛苦管理治疗反应的定量生物标志物。